Photo from Rashid Sayyid/X
Jun 11, 2024, 22:40
Rashid Sayyid: RW study of LuPSMA in VISION-eligible mCRPC patients
Rashid Sayyid, Urologic Oncology Clinical Fellow at University of Toronto, shared a post on X:
“RW study of LuPSMA in VISION-eligible mCRPC patients from expanded access program (UCLA, UCSF, Tulane, Johns Hopkins; n=117) compared to VISION phase 3 results.
- RW patients more likely to have received >1 ARPI (70% versus 46%), have worse PS, and have LN disease
- Similar OS (15.1) and PSA50 (42%)
- Increased incidence of Gr3+ lymphopenia in RW (34% versus 8%)
Results support use of LuPSMA in RW setting.”
Source: Rashid Sayyid/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 14:05
Nov 14, 2024, 13:49
Nov 14, 2024, 13:44
Nov 14, 2024, 13:37
Nov 14, 2024, 13:32
Nov 14, 2024, 13:29